By Mohammed Attallah | Biomelogic | Host Capacity Model
I have spent years researching small intestinal bacterial overgrowth and chronic gut dysfunction. Not from a textbook, and not from a comfortable academic distance. I have spent this time because I kept meeting the same person, over and over again — someone who had done everything right. Multiple courses of antibiotics. Herbal antimicrobials. Elimination diets. Low-FODMAP. Prokinetics. Probiotics. Breath tests. Specialists. And still — the bloating returns. The fatigue returns. The food reactions get worse instead of better, and the answers get thinner with every appointment.
They were not failing treatment. The treatment was failing them.
What I am sharing in this article is the most complete account of SIBO causation I know how to write, organized through a framework I have been building for years called the Host Capacity Model — a systems-biology approach to chronic gut dysfunction that repositions bacteria not as the cause of your suffering, but as the evidence of a deeper host-level failure that nobody has properly addressed.
I am going to walk you through every known cause of SIBO, every mechanism, the cutting-edge science published as recently as 2024, why current treatments are structurally incomplete, why the bacteria themselves are far more sophisticated than the standard story admits, the role of specific medications including SSRIs and PPIs, the impact of post-COVID infection on the gut nervous system, the genetic variants that determine who gets SIBO and how severely, and why the testing most people rely on may not be telling them what they think it is.
This is the article I wish existed when people first started finding me.
What SIBO Actually Is — And What It Isn’t
Small intestinal bacterial overgrowth is defined as an abnormal increase in the number and type of bacteria colonizing the small intestine — organisms that belong in the colon, now established in a compartment where they have no business being. The diagnostic threshold is more than 10³ colony-forming units per milliliter of small intestinal fluid, though this cutoff has been debated for decades and matters far less than the question almost no one is asking:
Why is the small intestine — a compartment that your body works extraordinarily hard to keep nearly sterile — suddenly hospitable to bacterial colonization?
The small intestine is not passively sterile. It is actively, aggressively, metabolically hostile to microbial colonization. Your body maintains this hostility through five overlapping defense systems operating simultaneously, every hour of every day. When all five hold, bacteria cannot gain a foothold. When one begins to crack, the others compensate. But when two or three fail at once — which is the actual situation in most people with chronic, treatment-resistant SIBO — the entire system collapses, and bacterial colonization becomes not just possible but inevitable.
Those five barriers are: gastric acid, which kills the majority of organisms before they ever reach the small intestine; the migrating motor complex, the interdigestive sweeping wave that clears residual bacteria between meals; bile acids and pancreatic enzymes, which suppress microbial growth and compete with bacterial nutrition; the ileocecal valve, which physically prevents colonic organisms from migrating backward; and finally — the one that most researchers stop short of — the mucosal oxygen economy, the metabolic state of the gut lining itself that makes the small intestinal environment fundamentally inhospitable to the wrong organisms.
The foundational reframe of everything that follows is this: in the Host Capacity Model, bacteria are not the cause of SIBO. They are the evidence of a cause. The question is never “how do I kill these bacteria?” The question is always “what failed in the host that made this environment survivable for them?” That distinction changes everything about how you approach recovery.
The MMC: The Gut’s Cleaning Crew — And Every Way It Gets Destroyed
The migrating motor complex is the most important defense against SIBO that almost no one outside of research circles fully understands. It is a cyclic wave of coordinated electrical and muscular activity that sweeps through the stomach and small intestine every 90 to 120 minutes during fasting — only during fasting, not during digestion — moving residual food particles, dead cells, and stray bacteria forward toward the colon. Its entire purpose is to make sure bacteria never have enough time in any one location to establish a colony.
When the MMC is healthy, bacteria are cleared faster than they can multiply. When the MMC is damaged — reduced in frequency, shortened in duration, or blocked in propagation — the small intestine becomes a stagnant reservoir. Bacteria stop being swept out. They feed. They multiply. They begin producing gases and metabolites that further slow transit, creating conditions that make their own removal progressively harder with time. Research shows that SIBO patients have roughly one-third as many MMC phase III events as healthy controls, with those events being approximately 30% shorter in duration. The housekeeper has effectively stopped showing up.
Here is every known mechanism by which the MMC is destroyed.
Cause 1: Food Poisoning and the Autoimmune Betrayal
This is the mechanism that changed how I think about SIBO — and the one most consistently missed in clinical practice, because patients often do not connect a bout of gastroenteritis years ago to the gut symptoms they are struggling with today.
When you get food poisoning from Campylobacter jejuni, Salmonella, Shigella, or pathogenic E. coli, these bacteria release a toxin called cytolethal distending toxin B — CdtB. Your immune system correctly identifies CdtB as foreign and mounts an antibody response. The infection resolves. Normal immune function. So far, so good.
But here is where the betrayal begins. CdtB shares structural homology with a protein in your own gut called vinculin — specifically at the N-terminal residues of the vinculin head domain, confirmed by mass spectrometry co-immunoprecipitation. Vinculin is a cytoskeletal anchoring protein expressed in the interstitial cells of Cajal — the c-Kit⁺/ANO1⁺ pacemaker cells that initiate the MMC’s electrical activity. Your immune system, having learned to recognize the shape of CdtB, begins attacking vinculin as collateral damage. Anti-vinculin autoantibodies form. They persist — damaging ICC populations and myenteric ganglia not for weeks but for months and years after the original infection has cleared.
The cascade runs as follows: bacterial gastroenteritis exposes the body to CdtB, the immune system produces anti-CdtB antibodies, molecular mimicry causes those antibodies to cross-react with vinculin in ICC cells and myenteric ganglia, vinculin expression drops, ICC density falls, MMC phase III amplitude and frequency collapse by more than 50%, bacterial stasis develops, SIBO establishes, and then the LPS produced by the overgrown bacteria amplifies further nerve damage — making the MMC progressively worse the longer the SIBO persists.
The higher the anti-vinculin antibody titers, the more severe, bloated, and difficult-to-treat the SIBO. This is measurable with the IBS-Smart blood test. Critically — you may not remember the food poisoning. Research shows that patients develop post-infectious SIBO months after an episode they barely registered at the time. The autoimmune damage outlasts the memory of the illness.
Cause 2: Chronic Psychological Stress — The Neuroscience Nobody Explains Properly
Chronic psychological stress does not cause SIBO metaphorically or indirectly. It causes SIBO through hard, documented molecular pathways — and it operates through at least three distinct mechanisms simultaneously.
When you are chronically stressed, your paraventricular nucleus activates the HPA axis, releasing corticotropin-releasing hormone. CRH acts not only on the pituitary but directly on CRH-R1 receptors on myenteric neurons in the enteric nervous system — meaning the gut wall itself receives and responds to stress signals completely independently of what the brain tells it to do. This direct ENS effect suppresses small intestinal motility at the source.
Simultaneously, cortisol elevation suppresses motilin release from duodenal M-cells. Motilin is the hormone responsible for triggering MMC phase III contractions. Without adequate motilin, the sweeping wave never gets the signal to initiate. Sympathetic norepinephrine — chronically elevated in stress states — acts on α2-adrenoceptors on enteric neurons, further suppressing acetylcholine release and collapsing the cholinergic drive that coordinates peristaltic reflexes.
Cortisol also attacks the mucosal barrier directly: it reduces MUC2 mucus production via glucocorticoid receptors on goblet cells, downregulates tight junction proteins ZO-1 and occludin, and suppresses secretory IgA production via glucocorticoid receptor-mediated B-cell inhibition in Peyer’s patches. The gut wall becomes thinner, more permeable, and less immunologically defended — all before a single bacterium has overgrown.
There is also a feedback loop that makes this self-perpetuating. Once SIBO establishes, the LPS produced by gram-negative Enterobacteriaceae interacts with the dorsal vagal complex in the brainstem, further suppressing MMC activity. And LPS also activates the HPA axis centrally, maintaining the cortisol elevation and sympathetic dominance that were driving the MMC suppression in the first place. Stress causes SIBO, and SIBO maintains the stress physiology that allows it to persist.
Cause 3: SSRIs — The Serotonin Paradox That Creates SIBO and Then Hides It
This section matters enormously because SSRIs are among the most commonly prescribed medications in the world, and their relationship with gut motility and SIBO is one of the most misunderstood aspects of gut dysfunction I encounter clinically.
To understand what SSRIs do to the gut, you first need to understand where serotonin lives. More than 95% of the body’s serotonin is produced in the gut — specifically in enterochromaffin cells and enteric serotonergic neurons. In the enteric nervous system, serotonin is not a mood molecule. It is a motility molecule. It coordinates peristaltic reflexes, secretory responses, and the entire mechanical apparatus that moves contents through the small intestine, including the MMC. The serotonin reuptake transporter — SERT, encoded by SLC6A4 — in the intestinal wall regulates how long 5-HT stays active at the enteric synapse. When serotonin is released, SERT clears it rapidly, terminating the signal. This rapid clearance is what allows the precise, rhythmic timing of MMC contractions.
When SSRIs block SERT, serotonin accumulates in the ENS. In the short term, this can either accelerate or slow motility depending on which receptor subtypes are dominant in a given patient. 5-HT₄ receptor activation is pro-motility. 5-HT₃ receptor activation can cause rapid transit and diarrhea. 5-HT₁A receptor activation on myenteric neurons is inhibitory — it reduces smooth muscle contraction and slows the gut. The net effect depends on the individual patient’s receptor profile, the specific SSRI being used, and how long they have been taking it.
But the long-term consequence is what matters most, and this is where the SIBO story begins. Chronic 5-HT excess in the ENS leads to receptor desensitization and downregulation. The 5-HT₄ receptors — the pro-motility receptors — desensitize most rapidly because they are the most continuously stimulated. What begins as variable motility effects gradually shifts, in many patients, toward a state of reduced pro-motility serotonergic signaling with preserved or even enhanced inhibitory signaling. The net long-term result in susceptible individuals is a hypomotility state — sluggish MMC, reduced propagative peristalsis, and stagnant small intestinal transit — that can persist even after the SSRI is discontinued, because the receptor changes represent structural ENS plasticity, not just pharmacological effects.
There is also a direct antimicrobial effect that cuts the other way. Several SSRI molecules — including fluoxetine and sertraline — have direct antimicrobial properties against certain gut bacteria at the concentrations that accumulate in the intestinal wall during oral dosing. This means SSRIs may partially suppress bacterial populations even as they are creating the motility conditions that favor overgrowth — which can mask the development of SIBO by keeping breath test readings ambiguous or falsely low, even while the patient is experiencing worsening gut symptoms. I have seen this pattern multiple times clinically: a patient on long-term SSRIs with progressive gut symptoms but a negative or borderline breath test, where the clinical picture strongly suggests SIBO but the test is suppressed by the antimicrobial properties of the drug itself.
Furthermore, SSRIs alter the composition of the gut microbiome directly. Multiple studies have shown that SSRIs reduce Lactobacillus populations, alter Firmicutes-to-Bacteroidetes ratios, and shift the small intestinal microbiome in ways that reduce colonization resistance against Enterobacteriaceae. This is not a theoretical concern — it has been demonstrated in both human and animal studies. The SSRI is simultaneously slowing the gut, reducing the beneficial bacterial populations that compete with pathogenic overgrowth, and potentially masking the resulting bacterial bloom on testing.
Paroxetine deserves specific mention because it has significant anticholinergic activity beyond its SERT inhibition. Acetylcholine is the primary neurotransmitter coordinating MMC contractions. Blocking muscarinic receptors with anticholinergic drugs is one of the most reliable ways to abolish MMC phase III activity. Paroxetine, among SSRIs, is therefore the highest-risk agent for SIBO development and persistence, combining serotonergic ENS disruption with direct anticholinergic MMC suppression.
The genetic layer here is also critically important. The 5-HTTLPR polymorphism in the promoter region of SLC6A4 creates short and long allele variants that alter SERT expression levels. Short allele carriers have lower SERT expression — they already have higher baseline synaptic serotonin in the ENS before any drug is introduced. When these individuals are put on SSRIs, the additional serotonin accumulation is far greater relative to baseline, and the receptor desensitization occurs faster and more severely. These patients are the ones who develop the most significant motility side effects from SSRIs and the most treatment-resistant SIBO as a consequence.
This does not mean SSRIs should not be used. It means that a patient with gut symptoms on a long-term SSRI — particularly paroxetine, and particularly if they carry the SLC6A4 short allele — needs the SSRI considered as a primary contributor to their gut dysfunction, not an incidental background medication.
Cause 4: Proton Pump Inhibitors — The Most Prescribed SIBO Risk Factor in History
Proton pump inhibitors are among the most widely prescribed medications in the world. In some populations, more than 10% of adults are taking them. They are prescribed for reflux, ulcers, H. pylori treatment, NSAID protection, and as a first-line response to almost any upper GI complaint. And they are, for a significant proportion of long-term users, a primary driver of SIBO — through mechanisms that go well beyond simply raising stomach pH.
The primary mechanism is well established: PPIs irreversibly block the hydrogen-potassium ATPase enzyme in gastric parietal cells, reducing gastric acid output by 90% or more and raising stomach pH well above 4. The acid kill step — which normally destroys the vast majority of organisms entering from food, water, swallowing, and environmental exposure — is effectively eliminated. Bacteria that would normally be killed in the stomach survive to reach the small intestine, where conditions should still suppress them through motility, bile, and immune defense. But if any of those downstream defenses are also compromised — which in most patients seeking help for gut symptoms they already are — the organisms that escape the stomach now find a permissive environment.
Studies have found SIBO in up to 50% of long-term PPI users, compared to 6% of healthy controls. The risk increases significantly after one year of continuous use, and the duration-dependence of this relationship suggests a progressive disruption of the small intestinal ecology with cumulative acid suppression.
But the acid story is only the beginning. PPIs also inhibit V-ATPase — a different proton pump — in macrophages throughout the gut mucosa. V-ATPase is required for lysosomal acidification, which is how macrophages kill bacteria after phagocytosing them. When V-ATPase is inhibited by PPIs, macrophages engulf bacteria normally but cannot digest them — the killing step inside the lysosome fails. This is a direct impairment of the innate immune defense in the small intestinal mucosa, operating completely independently of pH. A PPI user does not just have fewer bacteria killed in the stomach. They also have impaired bacterial killing by the immune cells lining the gut wall itself.
PPIs also alter mucus glycoprotein composition in ways that reduce the viscosity and protective function of the mucosal layer, making epithelial adhesion easier for pathogenic organisms. They modify gastrin levels — PPIs cause compensatory hypergastrinemia — which has its own effects on enterochromaffin cell proliferation and gut motility that are not yet fully understood but appear to contribute to the motility changes seen in long-term users.
At the microbiome level, PPI use is associated with specific shifts in small intestinal flora: increased Streptococcaceae, reduced Clostridiaceae, and an overall shift toward oral-type organisms that have survived the journey from the mouth because the acid gate was open. The REIMAGINE study — the most methodologically sophisticated microbiome analysis of SIBO to date — did find that PPI use produced measurable shifts in the small intestinal microbiome even in the absence of quantitative SIBO by culture. The ecology is being altered even when the threshold definition of overgrowth is not met.
The genetic modifier here is CYP2C19, which encodes the liver enzyme that metabolizes most PPIs. CYP2C19 poor metabolizers — who carry loss-of-function variants in both alleles — cannot clear PPIs efficiently, resulting in sustained higher drug levels and more prolonged acid suppression compared to normal metabolizers on the same dose. In CYP2C19 poor metabolizers, even standard PPI doses produce effects equivalent to much higher doses in normal metabolizers, substantially increasing the SIBO risk beyond what the prescribed dose would suggest.
There is also an important interaction between PPIs and the post-infectious autoimmune pathway described earlier. H. pylori eradication protocols universally include PPIs. After successful eradication, PPIs are often continued for acid suppression. But H. pylori eradication does not restore the atrophic gastritis-damaged parietal cell population. The patient is left with reduced acid-producing capacity plus ongoing PPI suppression, creating a combined hypochlorhydria that far exceeds what either factor alone would produce. And if the H. pylori infection was severe enough to trigger significant inflammation, the post-eradication period may also involve elevated anti-vinculin antibody titers from molecular mimicry with H. pylori’s own virulence proteins — meaning the patient has layered post-infectious autoimmune MMC damage on top of pharmacological acid suppression.
The clinical picture I see repeatedly: a patient who started a PPI years ago for reflux, never stopped, has been on it continuously, and now has SIBO that partially responds to antimicrobials and consistently relapses. The relapse is not mysterious. The cause is still present and active, every single day, with every dose of the drug. Treating the SIBO without addressing the PPI context is, in most of these cases, an exercise in futility.
Cause 5: Opioids — Prescription, Street, and Endogenous
Opioids bind µ-opioid receptors on myenteric inhibitory motor neurons, triggering Gi-coupled inhibition of acetylcholine release and suppression of neuronal nitric oxide synthase. MMC phase III contractions are the most vulnerable — they require the highest level of coordinated cholinergic signaling — and they are the first casualty of opioid exposure. This applies to prescription pain medications but also to endogenous opioids elevated by chronic HPA activation via the POMC pathway. Chronically stressed patients are effectively dosing their own gut with opioid-like compounds every day. The OPRM1 A118G variant alters µ-receptor binding affinity and increases individual susceptibility to this dysmotility.
Cause 6: Hypothyroidism
Thyroid hormone receptors TRα and TRβ are expressed directly on myenteric neurons and ICCs. Thyroid hormones directly upregulate contractile proteins and ANO1 pacemaker currents in the ICC. When T3 and T4 are low, ENS excitability falls, MMC phase III frequency decreases, and the entire small intestine slows globally. The DIO2 gene encodes the enzyme that converts T4 into active T3. DIO2 variants impair this conversion, producing a hypothyroid-like ENS state even when TSH appears perfectly normal — which is why this driver is frequently missed on standard thyroid panels.
Cause 7: Diabetic Autonomic Neuropathy
Chronic hyperglycemia drives the polyol and hexosamine pathways, generating advanced glycation end-products that cross-link proteins throughout the myenteric plexus and ICC network. AGEs activate RAGE receptors, triggering oxidative stress and apoptosis in the most vulnerable neural populations: nitrergic inhibitory neurons and the ICC pacemaker network. This damage is largely irreversible. SIBO was identified in 43% of diabetic patients with chronic diarrhea in published studies — not by coincidence, but because their enteric nervous systems are being progressively dismantled by glucose toxicity. The AGER gene encodes the RAGE receptor, and variants in AGER modulate the severity of AGE-driven tissue damage, determining who develops accelerated ENS degeneration at a given level of glycemic exposure.
Cause 8: The Methane Trap
Methanobrevibacter smithii consumes hydrogen gas produced by fermenting bacteria and converts it to methane. Methane acts as a neuromodulator — likely interacting with L-type calcium channels in smooth muscle cells — slowing propagative peristalsis by approximately 60% in infusion studies. The methanogens slow the gut. The slowed gut allows more fermentation. More fermentation produces more hydrogen. More hydrogen feeds more methanogens. The methane-dominant patient is caught in a self-sealing loop that antibiotics alone consistently fail to break.
Cause 9: Post-COVID Vagal Neuropathy — The New Epidemic of SIBO Nobody Is Diagnosing
This section deserves extended treatment because it represents a genuinely new mechanism that has emerged since 2020 and that the gastroenterology field has been slow to integrate into its clinical thinking about SIBO. Post-COVID gut dysfunction is real, mechanistically grounded, and being misdiagnosed or undiagnosed at enormous scale.
SARS-CoV-2 enters cells through the ACE-2 receptor. ACE-2 is expressed not only in lung tissue but throughout the vagus nerve — in all structural elements including the nodose ganglion, the vagal fascicles, the perineurium, and the nerve endings that project into the gut wall. This means SARS-CoV-2 has direct access to the primary parasympathetic nerve that controls small intestinal motility.
When the virus infects vagal tissue, it triggers an inflammatory response characterized by infiltrating monocytes and CD8⁺ T cells around vagal brainstem nuclei, with strong enrichment of interferon signaling genes in vagal nerve tissue. This has been confirmed by histopathological analysis of post-mortem COVID-19 patients, published in peer-reviewed literature. The axons in these studies showed no overt degeneration — the inflammation does not immediately destroy the nerve fibers. But the inflammatory environment surrounding the vagal nuclei is sufficient to produce profound and lasting autonomic dysfunction that affects every organ system the vagus controls.
For the gut, this dysfunction is direct and specific. The vagus nerve provides the parasympathetic drive that initiates and maintains MMC contractions. Specifically, motilin-induced phase III MMC contractions require intact vagal cholinergic signaling through the MLNR/GHSR receptor on ICCs and myenteric neurons. When vagal efferent activity falls — due to the neuroinflammation surrounding vagal nuclei — the MMC loses its primary initiating signal. Gut transit slows globally. The small intestine becomes a stagnant environment. And the bacteria that are normally cleared by the sweeping wave begin to accumulate.
The timeline of this presentation is characteristic and diagnostically useful. The patient typically had no significant gut history before COVID-19. Then, six to twelve months after the acute infection — sometimes longer — they begin developing bloating that was not there before, new food intolerances, post-meal fatigue that suggests malabsorption, transit changes in either direction, and sometimes significant weight loss or inability to maintain weight. These symptoms are consistent with established SIBO on top of post-viral vagal dysfunction.
What makes post-COVID SIBO particularly difficult to treat is that the driving mechanism — vagal neuroinflammation — is ongoing and not addressed by any standard SIBO protocol. Rifaximin will reduce the bacterial load. Prokinetics will provide some MMC stimulation. But if the vagal inflammation is persistent — which in long COVID appears to be the case in a significant proportion of patients — the motility deficit will continue generating the stasis that allows SIBO to re-establish.
There is also an autoimmune dimension to post-COVID gut dysfunction that is separate from the vagal neuropathy. COVID-19 triggers a broad autoimmune response in susceptible individuals — autoantibodies against a range of host proteins have been documented post-COVID, including against autonomic nervous system components. Anti-ganglionic acetylcholine receptor antibodies have been identified in some post-COVID patients — these are the same antibodies seen in autoimmune autonomic ganglionopathy, a condition characterized by severe autonomic dysfunction including profound gut dysmotility. This represents a post-COVID autoimmune MMC failure that is mechanistically identical to the post-infectious vinculin autoimmunity described earlier, but with different target proteins and a different triggering pathogen.
The patient with post-COVID SIBO who also has POTS, exercise intolerance, brain fog, and mast cell activation — a combination that is now being called long COVID — is dealing with a syndrome in which the gut dysmotility is one manifestation of a systemic autonomic and immune dysregulation, not a primary gut disease. Treating the gut in isolation will produce partial, unsustained results. The autonomic and immune context has to be part of the picture.
I have been working with post-COVID gut cases in my practice, and they represent some of the most complex presentations I encounter — precisely because the causation is multilayered, the testing is often ambiguous or misleading, and the standard gut-focused approach consistently fails to address the vagal and autoimmune drivers.
Cause 10: Structural Causes — ICV, Adhesions, hEDS
The ileocecal valve prevents colonic bacteria — present at concentrations a thousand times higher than the small intestine — from migrating backward. ICV competence requires intact muscular sphincter tone, intact neurological reflexes, and intact connective tissue support. In hypermobile Ehlers-Danlos Syndrome, COL3A1 and COL5A1 variants weaken fascial integrity throughout the body including at the ICV, producing laxity that no dietary or antimicrobial treatment can compensate for. In dysautonomia, the neurological reflex fails. In patients with endometriosis, the valve is disrupted mechanically. Visceral ptosis — organs dropping out of position — creates functional blind loops. The hEDS patient typically has three simultaneous SIBO drivers: ICV laxity, dysautonomia-driven MMC failure, and MCAS-mediated ENS disruption. No single-modality treatment can resolve this.
Adhesions from surgery, pelvic inflammatory disease, or endometriosis create both mechanical obstruction of luminal flow and disruption of mechanosensory feedback to the ENS. Diverticula create anatomical pockets of stasis outside the main luminal flow that the MMC cannot clear.
Genetic Predisposition: Who Gets SIBO and Why
One of the most important aspects of SIBO that is almost never discussed is the genetic architecture that determines why the same environmental exposures — a bout of food poisoning, a year on PPIs, a period of high stress — produce chronic SIBO in one person and a transient nuisance in another. Genetics does not cause SIBO directly. But genetics determines the thresholds at which each barrier fails, the severity of the failure when it occurs, and the degree to which the host can repair and recover. Understanding your genetic architecture is central to understanding your individual SIBO pattern.
Here are the most clinically relevant genetic variants in SIBO, organized by the system they affect.
Motility and ENS genetics:
TLR4 variants affect pathogen recognition efficiency and determine the magnitude of the immune response to CdtB during gastroenteritis — which in turn determines the severity of the molecular mimicry autoimmune response to vinculin. Patients with TLR4 variants that produce exaggerated pathogen responses are more likely to develop severe post-infectious MMC damage from the same gastroenteritis exposure.
IL-10 variants affect anti-inflammatory resolution capacity. IL-10 is the primary brake on the autoimmune response after infection. Patients with IL-10 variants that reduce cytokine production or signaling maintain the anti-vinculin autoimmune attack for longer after the infection has resolved, producing more sustained ICC damage and more severe MMC failure.
FOXP3 and PTPN22 variants affect regulatory T-cell function. These are the immune cells responsible for recognizing self proteins — like vinculin — and calling off the attack. When FOXP3 or PTPN22 function is impaired, regulatory T cells fail to suppress the anti-vinculin response, and the autoimmune damage to ICCs becomes self-sustaining rather than self-limiting.
OPRM1 A118G affects µ-opioid receptor binding affinity. This variant increases receptor sensitivity to both exogenous and endogenous opioids, meaning that the same level of stress-induced POMC activation — or the same prescription opioid dose — produces substantially more MMC suppression in carriers than in non-carriers.
DIO2 Thr92Ala is one of the most clinically underappreciated variants in gut health. DIO2 encodes type II deiodinase, which converts T4 into the active T3 form within cells — independently of serum thyroid hormone levels. The Thr92Ala variant reduces intracellular T3 availability in target tissues including the ENS. Patients carrying this variant can have perfectly normal TSH and free T4 levels on standard thyroid panels and simultaneously have an ENS that is operating in a hypothyroid-like state due to impaired local T3 conversion. These patients frequently respond to thyroid support — particularly T3-containing preparations — with significant improvement in gut motility that standard thyroid testing would never have predicted.
AGER variants affect RAGE receptor sensitivity to advanced glycation end-products. This determines how aggressively hyperglycemia damages the ENS in diabetic patients and also how much ENS AGE-mediated damage accumulates in non-diabetic patients exposed to high glycemic loads over time.
Acid and chemical barrier genetics:
CYP2C19 variants determine PPI metabolism speed. Poor metabolizers accumulate higher drug levels with standard doses, producing deeper and more prolonged acid suppression. Ultrarapid metabolizers may require higher doses for therapeutic effect and are at lower SIBO risk from standard PPI dosing.
HLA-DR alleles associated with autoimmune gastritis determine susceptibility to anti-parietal cell antibody production — the autoimmune mechanism that destroys parietal cells and produces permanent achlorhydria. This is the same autoimmune pathway that causes pernicious anemia and is distinct from H. pylori-mediated gastritis.
Mucosal defense and immune genetics:
FUT2 encodes the enzyme that determines secretor status — whether blood group antigens are secreted into gut mucus. Non-secretors carry FUT2 loss-of-function variants that alter the mucus glycoprotein composition in ways that reduce the diversity of commensal bacteria in the small intestine and impair colonization resistance against pathogenic organisms. Non-secretors have significantly higher rates of gut dysbiosis and are more susceptible to pathogen colonization broadly.
IGHA1 and IGHA2 gene deletions produce selective IgA deficiency — a primary immune condition affecting approximately 1 in 600 individuals. Selective IgA deficiency removes the primary mucosal antibody that coats bacteria, prevents epithelial adhesion, and facilitates clearance. Patients with selective IgA deficiency have a virtually permanent structural predisposition to gut bacterial overgrowth that no antimicrobial protocol can compensate for without addressing the underlying immune gap.
SLC6A4 5-HTTLPR short allele reduces SERT expression in the ENS, creating higher baseline synaptic serotonin levels. When these individuals are prescribed SSRIs, the additional serotonin accumulation is disproportionately large, receptor desensitization occurs more rapidly, and the motility side effects — including MMC suppression — are more severe and more persistent.
FKBP5 rs1360780 prolongs glucocorticoid receptor signaling by slowing the dissociation of cortisol from its receptor complex. Carriers have exaggerated and prolonged cortisol effects from the same stressor, making stress-induced MMC suppression, mucus layer thinning, and sIgA depletion more severe. This variant is associated with increased risk of HPA axis dysregulation after stress exposure and is particularly relevant for the stress-to-SIBO pathway.
CRHR1 variants alter the sensitivity of CRH receptors throughout the brain and ENS. Patients with high-sensitivity CRHR1 variants have exaggerated ENS responses to CRH, meaning the direct stress-to-gut-motility pathway described earlier is amplified beyond what the systemic cortisol level alone would predict.
Oxygen economy and metabolic genetics:
PPARG — the gene encoding PPAR-γ — has variants that affect the baseline expression and activity of this receptor in colonocytes and small intestinal epithelial cells. Low-function PPARG variants reduce the efficiency of fatty acid oxidation in epithelial cells, meaning the physiological hypoxia gradient that protects the gut is maintained less robustly under baseline conditions and fails at lower levels of inflammatory insult. These patients are more susceptible to oxygen economy collapse from any upstream trigger.
NOS2 variants affect iNOS expression and nitrate production in response to inflammatory stimuli. High-expression NOS2 variants produce more nitrate in the inflamed small intestinal lumen, providing more electron acceptors for the NarG nitrate reductase system in Enterobacteriaceae — meaning the bacterial bloom in response to epithelial metabolic failure is more rapid and more severe in these individuals.
SLC5A8 encodes the primary butyrate transporter in colonocyte membranes. Epigenetic silencing of SLC5A8 — which can be driven by inflammatory exposures, dysbiosis itself, and certain dietary patterns — reduces butyrate uptake by colonocytes even when luminal butyrate is present. This breaks the butyrate-PPAR-γ feedback loop from the transport step rather than the receptor step, producing oxygen economy failure even in patients who appear to have adequate dietary fiber intake and detectable butyrate on stool testing.
Connective tissue and structural genetics:
COL3A1 and COL5A1 variants in hypermobile Ehlers-Danlos Syndrome produce connective tissue laxity that affects the ileocecal valve, the mesenteric supports, and the structural integrity of the gut wall itself. The prevalence of SIBO in hEDS is extraordinarily high — estimates range from 50% to over 80% in published cohorts — precisely because the structural barrier is compromised at the genetic level from birth.
This genetic layer matters clinically for one specific reason: it explains why the same environmental exposure produces permanent SIBO in one person and a transient nuisance in another. It also means that certain patients — those carrying combinations of these variants — have a fundamentally lower threshold for SIBO development and a fundamentally higher threshold for sustained recovery. These patients need a different approach from the start, not the same approach applied more aggressively.
Bile Acids: The Forgotten Antimicrobial System and What Happens When They Turn Toxic
Bile acids are potent antimicrobials in the small intestine and signaling molecules that regulate the small intestinal microbiome through the FXR-FGF19 axis. Bile acid activation of FXR in the ileal epithelium drives FGF19 secretion and directly stimulates production of Angiogenin-4 — an antimicrobial peptide that suppresses bacterial growth in the small intestinal lumen. Post-cholecystectomy patients lose the episodic bile bolus and have continuous low-level bile trickle that never reaches the FXR activation threshold. Genetic variants in SLC10A2, CYP7A1, and FGFR4 modulate individual bile acid pool size and antimicrobial competence.
But there is a second side of this story that almost no one discusses: what happens to bile acids once SIBO is established.
When bacteria overgrow the small intestine, they express bile salt hydrolase enzymes that prematurely deconjugate bile acids in the small intestinal lumen. Conjugated bile acids — glycocholate, taurocholate — are water-soluble, efficiently reabsorbed in the ileum via the SLC10A2 transporter, and recirculated in the enterohepatic cycle. Deconjugated bile acids are a completely different story.
Free deconjugated bile acids are poorly water-soluble. They precipitate in the small intestinal lumen. They are directly cytotoxic to enterocytes — intercalating into membrane phospholipid bilayers, disrupting tight junction proteins, and producing a chemical burn of the intestinal surface. This is not a metaphor. The mucosal biopsy of a patient with significant SIBO-driven bile acid deconjugation shows villous blunting, brush-border disruption, increased intraepithelial lymphocytes, and a pattern of mucosal injury that looks like early celiac disease or tropical sprue — because the mechanism of injury is similar in some respects: chemical damage to the enterocyte surface by toxic luminal compounds.
Deconjugated bile acids also act as secretagogues via TGR5 receptors on colonocytes when they spill into the colon, stimulating fluid and electrolyte secretion and producing the osmotic diarrhea that many SIBO patients cannot understand given how carefully they are controlling their diet. The diarrhea is not from food. It is from the chemical consequences of their own bacteria’s metabolism.
The bile acid deconjugation also removes the antimicrobial properties of the bile that were helping to contain the bacterial overgrowth in the first place — completing a vicious cycle: bacteria cause bile acid deconjugation, deconjugated acids damage the intestinal surface, the damaged surface becomes more permeable to LPS, more LPS enters the portal circulation, the liver responds with inflammatory signaling, and the bile acid pool itself becomes progressively depleted and dysfunctional as the enterohepatic circulation is disrupted.
Long-standing SIBO with significant bile acid deconjugation will produce fat-soluble vitamin deficiencies — A, D, E, K — because fat absorption depends on intact micelle formation that conjugated bile acids provide. Vitamin D deficiency then impairs mucosal immune function. Vitamin K deficiency affects coagulation and also bone health. Vitamin A deficiency impairs goblet cell function and reduces MUC2 mucus production. The nutritional consequences of bile acid disruption in chronic SIBO extend far beyond the gut.
This is why some SIBO patients develop apparent fat intolerance even after antimicrobial treatment. The bile acid pool has been structurally disrupted, and normalizing it takes time and specific support that most SIBO protocols do not account for.
The Oxygen Economy and the Host Capacity Model
Now I want to take you somewhere most SIBO researchers have not gone — into the metabolic interior of the gut lining itself. Because this is where all the upstream causes converge, and this is where my research has been focused for years.
In a healthy gut, the epithelial cells lining the small and large intestine consume oxygen in vast quantities to fuel mitochondrial beta-oxidation of butyrate and other short-chain fatty acids. This oxygen consumption is so extensive that it creates a state of physiological hypoxia in the gut lumen — oxygen levels drop below 1% near the mucosal surface. This is not an accidental side effect. It is a designed feature of the system. It is what makes the gut lumen hostile to the organisms that do not belong there.
A 2024 study confirmed that butyrate not only fuels beta-oxidation but also stabilizes hypoxia-inducible factor through noncompetitive inhibition of HIF prolyl hydroxylases. Butyrate is simultaneously the energy source and the regulatory signal that maintains the oxygen gradient. The gut lining is actively preserving its own hostility to the wrong organisms using the metabolic products of the right organisms.
When colonocyte metabolism is disrupted — by any of the upstream causes in this article — the cell can no longer sustain beta-oxidation. It switches to glycolysis. Glycolysis consumes far less oxygen. The oxygen that was previously being burned as fuel leaks into the lumen. Simultaneously, NF-κB-driven inflammation upregulates iNOS, the enzyme encoded by NOS2, and nitrate begins accumulating in the lumen. PPAR-γ — the nuclear receptor that drives fatty acid oxidation — is downregulated by TNF-α and low butyrate, breaking the feedback loop that maintained the gradient.
Now the ecological shift becomes inevitable.
Facultative anaerobes — E. coli, Klebsiella, Enterococcus, Citrobacter — possess the NarG nitrate reductase system. They use oxygen and nitrate as alternative electron acceptors. The failing epithelium has just produced precisely the environment they are optimized to exploit. Obligate anaerobes — the beneficial butyrate-producing populations — are simultaneously suppressed by the oxygen now present. A 2024 study published in Cell Host and Microbe confirmed this directly: disrupting mitochondrial function in intestinal epithelial cells alone, without any other intervention, was sufficient to cause dysbiosis and expansion of pathogenic taxa.
The bacteria did not cause the problem. The metabolic failure of the host cell invited them in.
This is the Host Capacity Model. SIBO is not a bacterial problem that secondarily damages the gut lining. It is a host cell metabolic failure — driven by any combination of the upstream causes in this article — that creates a permissive luminal environment in which the wrong organisms cannot help but establish. The CD38-NAD⁺ depletion cascade, SLC5A8 epigenetic silencing of the butyrate transporter, colonocyte mitochondrial dysfunction, PPAR-γ downregulation, iNOS-driven nitrate accumulation, and the resulting oxygen-nitrate-lactate leak into the lumen — these are the mechanistic nodes where host capacity fails. The bacteria are the consequence. Until this layer is addressed, treatment will always be temporary.
Why the Bacteria Are Far More Sophisticated Than You Have Been Told
The organisms that establish in SIBO are not passive passengers. They are metabolically sophisticated survivors optimized over billions of years to persist in hostile environments. The assumption that a two-week antibiotic course will eliminate them cleanly and permanently is not supported by what we know about their biology.
The Enterobacteriaceae dominating SIBO — E. coli, Klebsiella, Citrobacter — are the most metabolically flexible organisms in the gut. They are facultative anaerobes with layered electron transport systems: they use oxygen when present, switch to nitrate respiration via NarG when oxygen is limited, switch to fumarate reduction when nitrate is gone, and fall back on fermentation when none of the above is available. They can generate energy under almost any condition the gut can produce. The NarG system specifically allows E. coli to use nitrate — which becomes abundant in the iNOS-upregulated, inflamed small intestine — as a terminal electron acceptor with nearly the same energy yield as oxygen. They do not need the environment to be aerobic. They just need the host’s metabolism to be failing, which provides both the oxygen leak and the nitrate simultaneously.
Iron and Bacterial Survival
Every pathogenic bacterium establishing in the small intestine requires iron to survive, replicate, and mount biofilm defenses. Pathogenic E. coli and Klebsiella produce siderophores — high-affinity iron-chelating molecules that scavenge iron from the local environment with extraordinary efficiency. Enterobactin, the primary E. coli siderophore, has one of the highest known affinities for iron of any biological molecule. These organisms strip the local iron supply and import it into themselves, depriving both the host tissue and competing organisms of a resource that every cell in the gut needs.
The host counter-response is hepcidin elevation — the master iron regulatory hormone rises during infection, sequestering iron into ferritin and reducing serum availability through the mechanism called nutritional immunity. But in chronically inflamed small intestine, this system becomes dysregulated. Chronic low-grade inflammation maintains elevated hepcidin even outside acute infection, creating functional iron deficiency at the cellular level — the mitochondria that need iron as a cofactor for electron transport chain complexes are starved — while the bacteria are extracting iron from the epithelial surface through siderophore mechanisms that operate independently of systemic iron status.
The clinical picture: a patient with normal or even elevated ferritin on labs who is exhausted, cognitively foggy, unable to sustain physical activity — and with bacteria in their small intestine actively winning the iron competition that their own mitochondria need to function. The worse the mitochondria fail for lack of iron and other cofactors, the worse the colonocyte oxygen economy becomes, the better the environment for the bacteria, the more iron they sequester. The loop deepens.
Biofilm: Why Killing Individual Bacteria Is Often the Wrong Strategy
In chronic SIBO presentations, the responsible organisms are not floating freely in the small intestinal lumen. They are living inside organized biofilm communities — structured three-dimensional matrices embedded in self-produced polymer scaffolds made of exopolysaccharides, extracellular DNA, and proteins.
Inside biofilm, bacteria communicate through quorum sensing — chemical signaling systems that allow coordination of behavior across the entire community, collective adjustment of gene expression, and unified responses to environmental threats including antibiotics. Bacteria inside biofilm are 100 to 1000 times more resistant to antibiotics than their free-floating counterparts. This is not classical genetic antibiotic resistance. It is structural and physiological resistance that operates regardless of whether the organism carries resistance genes.
Bacteria inside biofilm can also enter persister cell dormancy — a metabolically suppressed state in which they are almost entirely insensitive to antibiotics that work by targeting active metabolic processes. When the antibiotic course ends, these persister cells resume normal metabolism and repopulate the community from within. This is one of the primary mechanisms behind SIBO relapse after apparently successful treatment — not reinfection from outside, but re-emergence from surviving biofilm populations that were never eliminated.
Immune Evasion
The bacteria establishing in SIBO have evolved specific mechanisms to survive immune defense. E. coli and Klebsiella modify their LPS structure to reduce TLR4 recognition. They express outer membrane proteins that interfere with complement activation. They produce IgA proteases that cleave secretory IgA — the primary mucosal antibody whose job is to coat and neutralize them. Within biofilm, bacteria are largely invisible to adaptive immune surveillance. T cells and B cells cannot effectively target organisms encased in a polymer matrix. The biofilm environment also contains immunosuppressive signals that dampen local immune activation and promote a tolerogenic state in surrounding tissue — the immune system progressively stops recognizing the biofilm community as a threat and begins treating it as background noise.
Antibiotic Effectiveness: What the Literature Actually Shows
Rifaximin has an eradication rate of approximately 70-73% in meta-analysis across 32 studies. Relapse rates are 12.6% at three months, 27.5% at six months, and 43.7% at nine months. The median symptom relief duration is approximately six months. Herbal antimicrobials show equivalent eradication rates — which confirms that the limiting factor is not killing power but the structural environment that makes recolonization inevitable.
Enterobacteriaceae driving SIBO have well-documented antibiotic tolerance mechanisms: efflux pump upregulation that actively expels antibiotics from the cell, outer membrane porin modification that reduces antibiotic uptake, and the persister cell dormancy described above. Some strains carry extended-spectrum beta-lactamases. Some have acquired carbapenem resistance through horizontal gene transfer. The organisms driving SIBO are the same organisms driving the antibiotic resistance crisis in hospitals globally. Treating them with the assumption that a short antibiotic course will cleanly resolve the problem reflects an incomplete understanding of their biology.
Why I Do Not Trust Breath Testing the Way Most People Do
The hydrogen and methane breath tests measure gas produced by bacterial fermentation as a substrate moves through the gut. An early rise in hydrogen — above 20 parts per million within 90 minutes — or methane above 10 parts per million is considered positive for SIBO.
The problems are significant. First, the transit time assumption: the test assumes standard orocecal transit time and uses early peak timing to infer small intestinal location of fermentation. But transit time is highly variable, and it is most abnormal in exactly the patients — dysmotility patients — where SIBO is most likely. Fast transit produces false positives. Slow transit produces false negatives. The test is least reliable in the population where accuracy matters most.
Second, sensitivity is approximately 52% for lactulose breath test versus culture, with specificity around 86%. A negative test does not rule out SIBO. A positive test in a fast-transit patient does not confirm it.
Third, the test measures gas — a metabolic byproduct — not bacteria directly. It cannot identify which organisms are present, whether they are in planktonic or biofilm form, where exactly in the small intestine they are located, what the host mucosal response is, or what the oxygen economy state is. It is a low-resolution indirect proxy for a complex biological situation.
Fourth, hydrogen sulfide — produced by sulfate-reducing bacteria and increasingly recognized as an important SIBO subtype with a distinct clinical picture — is not measured by most standard breath test panels at all. H₂S-dominant SIBO patients may test completely negative on standard panels while having significant overgrowth.
I use the breath test as one data point among many, not as the definitive arbiter. I am more interested in the complete clinical picture — symptom patterns, dietary responses, medication history, genetic context, hormonal environment, prior infections, and the pattern of barrier failures — than in a single gas measurement with known limitations in precisely the population I work with.
The Death Spiral: What SIBO Does Over Time
Once SIBO establishes, the bacteria systematically dismantle remaining defenses.
Bile acid deconjugation removes the antimicrobial bile bolus, produces toxic deconjugated acids that damage the enterocyte surface, drives osmotic diarrhea, and depletes fat-soluble vitamins as described.
Villous blunting and brush-border enzyme loss develop from ongoing bacterial toxin exposure and deconjugated bile acid damage. Lactase, sucrase-isomaltase, and other disaccharidases are lost. New food intolerances emerge — not because of new immune sensitivities but because the enzymatic machinery for digestion is being destroyed.
Fermentation gas — hydrogen, methane, hydrogen sulfide — creates luminal distension that mechanically impairs MMC propagation. The gut slows further. More substrate is available for fermentation. The cycle accelerates.
LPS from gram-negative bacteria engages TLR4, generating TNF-α that suppresses MMC activity via the dorsal vagal complex and drives hepatic inflammation — contributing to metabolic dysfunction-associated steatotic liver disease in a significant subset of long-standing SIBO patients.
Vitamin B12 depletion follows as bacteria consume cobalamin and compete with host absorption at the ileal receptor. B12 deficiency worsens ENS function, deepening the motility defect.
PPAR-γ downregulation from TNF-α exposure breaks the butyrate-PPAR-γ-beta-oxidation loop permanently. The oxygen economy collapses. The Proteobacteria bloom becomes self-sustaining — no longer dependent on the original upstream cause. The environment now maintains itself.
Mast cell activation amplifies everything. LPS activates TLR4 on mucosal mast cells, driving histamine release, further ENS disruption, and increased permeability. In patients with pre-existing MCAS tendency, this triggers systemic mast cell crisis — extending symptoms to skin, neurological, cardiac, and immune systems.
By this stage, the patient is no longer dealing with a gut motility problem. They are dealing with a systemic metabolic-immune-neurological crisis centered in the gut, with ramifications extending through every organ system connected to the enteric nervous system and the portal circulation.
Why Current Treatments Are Structurally Incomplete
Rifaximin and antibiotics reduce bacterial load and create a temporary window of improvement. They do not restore the MMC. They do not repair the vinculin-ICC axis. They do not reverse PPAR-γ downregulation. They do not address MCAS-driven ENS disruption. They do not fix ICV laxity. They do not eliminate biofilm communities. They do not correct iron economy disruption. The environment that invited the bacteria remains intact when the course ends.
Herbal antimicrobials show equivalent eradication rates to rifaximin — confirming that the limiting factor is not killing power but the structural environment. Same fundamental limitation, different bottle.
Low-FODMAP diet reduces fermentable substrate and temporarily reduces symptoms. It does not eradicate SIBO. Long-term very low FODMAP intake may worsen dysbiosis by starving beneficial anaerobes and further reducing butyrate production — worsening the oxygen economy failure it was meant to address symptomatically.
Elemental diet achieves approximately 80% eradication by starving bacteria of complex substrates. It is extremely difficult to sustain, does not restore MMC or mucosal integrity, and has high relapse rates when normal eating resumes.
Prokinetics are the most mechanistically sensible addition because they address one of the primary structural causes — MMC failure. When combined with antimicrobials, they meaningfully reduce relapse rates. But they do not address anti-vinculin autoimmunity, oxygen economy collapse, structural causes, or MCAS.
The core problem: SIBO is not one disease. It is a clinical endpoint reached through multiple completely different mechanistic pathways. A post-infectious autoimmune patient with vinculin damage needs something fundamentally different from a post-COVID vagal neuropathy patient, who needs something different from an hEDS patient with ICV laxity and MCAS, who needs something different from a long-term PPI user on paroxetine with methane-dominant IMO and a DIO2 variant. Treating all of them with the same antibiotic protocol and expecting the same results is not evidence-based medicine. It is pattern-matching to a label without understanding the mechanism.
The Host Capacity Model: What I Have Been Building
Over years of research into SIBO, chronic gut dysfunction, mast cell activation, the epigenetics of gut barrier function, and the intersection of metabolic biology and microbial ecology, I have developed a framework I call the Host Capacity Model.
The central argument is that SIBO — and most chronic gut dysfunction — is not primarily a microbial problem. It is a host capacity problem. Host capacity refers to the metabolic, immune, structural, and neurological capacity of the gut lining and its supporting systems to maintain conditions that make the small intestine inhospitable to the wrong organisms. When host capacity is high, bacteria cannot establish regardless of exposure. When host capacity falls — through any combination of the mechanisms described in this article — establishment becomes possible, and eventually inevitable.
The model is organized around the colonocyte as the central unit of analysis. Not the microbiome, not the bacteria, not the breath test result — the cell that lines the intestine and whose metabolic state determines whether the lumen is hospitable or hostile. The CD38-NAD⁺ depletion cascade, SLC5A8 epigenetic silencing of the butyrate transporter, colonocyte mitochondrial dysfunction, PPAR-γ downregulation, and the resulting oxygen-nitrate-lactate leak — these are the mechanistic nodes where host capacity fails.
The model also encompasses the epigenetic layer — how DNMT3A, TET2, and H3K9 methylation states regulate the expression of genes governing colonocyte metabolism and immune gate function. These epigenetic states are themselves downstream of NAD⁺ and α-ketoglutarate availability, which are downstream of colonocyte bioenergetic status. The entire causal hierarchy flows from host metabolic capacity downward to microbial ecology — never the other way around.
I work with this framework clinically with complex, treatment-resistant cases — patients who have been through multiple standard protocols, who have ambiguous or negative breath tests but clear clinical SIBO pictures, who have MCAS and POTS and hEDS and long COVID layered together, who have been told their problems are functional or psychosomatic. These are the patients whose complexity most interests me and whose recovery requires the most rigorous mechanistic thinking.
I am not going to give you a protocol here, because a protocol without a proper assessment of your individual cause architecture is exactly the kind of treatment that produces temporary results and lasting frustration. What I do is mechanistic work: identifying the specific pattern of host capacity failure in each individual and building an approach that addresses root causes in the sequence that the biology actually supports.
What This Means for You
If you have been through multiple rounds of antibiotics, improved temporarily, and relapsed — you are not failing treatment. The treatment is failing to address the cause.
The question you need answered is not which antibiotic will work this time. It is: which of your barriers has failed, in what combination, amplified by which genetic variants, compounded by which medications, triggered by which prior infections, and what does it take to restore host capacity in the right order?
That is a different question entirely. And it is the question my work is organized around answering.
You can reach me at research@biomelogic.net. My ongoing research is published at Substack @mohammedattallah and Medium @mattallah922.
Share this article if you know someone who has been cycling through the same failed treatments without understanding why. They deserve a complete explanation.
— Mohammed Attallah, Biomelogic